This week Applied DNA Sciences will be participating in the 3rd Annual mRNA Process Development & Manufacturing Summit and will co-host seminar with mRNA CDMO Kudo Biotechnology. #syntheticbiology #EnzymaticDNAProduction #PCR #mRNA #GeneticMedicine #NucleicAcidBasedTherapies #DNAInnovation #CellFreeDNAProduction #SyntheticDNA #BiotechInnovation Aaron Chung Clay Shorrock Atsuko Sakurai-Sangria
LineaRx, Inc.
生物技术研究
Stony Brook，NY 310 位关注者
The enzymatically-produced alternative to plasmid DNA
关于我们
LineaRx, Inc. (an Applied DNA Sciences, Inc. (NASDAQ: APDN) company) delivers enzymatically produced LinearDNA? as an alternative to current plasmid-based DNA manufacturing processes with advantages of speed, purity, and scalability to support the next generation of nucleic acid-based therapies. Manufactured by a proprietary, large-scale polymerase chain reaction (‘PCR’)-based manufacturing platform, LinearDNA allows for the rapid and efficient cell-free production of high-fidelity DNA sequences. LinearDNA is relevant to a broad array of advanced therapeutics, including mRNA production, DNA vaccines, cell and gene therapies, as well as numerous veterinary medicine applications. Formed in 2018 to commercialize our parent company’s 20+ years of experience and leadership in enzymatic DNA production, LinearRx stands ready to deliver a new generation of DNA for the next generation of medicines. LineaRx, We are DNA Made Simple.
- 网站
-
https://www.linearxdna.com/
LineaRx, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Stony Brook，NY
- 类型
- 上市公司
- 领域
- Biotherapeutics、Linear DNA和DNA Vaccines
地点
-
主要
获取路线
US，NY，Stony Brook，11790
动态
-
Applied DNA Sciences has received a follow-on order valued at more than $500,000 for a quantity of Linea? DNA from a global manufacturer of?in vitro?diagnostics (IVDs). #syntheticbiology #EnzymaticDNAProduction #PCR #mRNA #GeneticMedicine #NucleicAcidBasedTherapies #DNAInnovation #CellFreeDNAProduction #SyntheticDNA #BiotechInnovation
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
https://linearxdna.com
-
Register today for our Luncheon Tech Talk with Kudo Biotechnology! Speakers Atsuko Sangria, Ph.D. and Aaron Chung will discuss how the Linea? IVT platform can support rapid dsRNA-mitigated mRNA manufacturing. https://lnkd.in/eaaT8bDU #mRNAtherapeutics #LNP #pDNA
-
-
There's still time to register for our Luncheon Tech Talk with Kudo Biotechnology! Speakers Atsuko Sangria, Ph.D. and Aaron Chung will present proof-of-concept study data and a case study demonstrating how the Linea? IVT platform can support rapid dsRNA-mitigated mRNA manufacturing. #mRNAtherapeutics #LNP #pDNA
-
-
We're hosting a Luncheon Tech Talk with Kudo Biotechnology! Speakers Atsuko Sakurai-Sangria, Ph.D. and Aaron Chung will present proof-of-concept study data and a case study demonstrating how the Linea? IVT platform can support rapid dsRNA-mitigated mRNA manufacturing. #mRNAtherapeutics #LNP #pDNA
-
-
Applied DNA will present a poster, ’Reduction of dsRNA Contamination in High-Yield mRNA Production', at the 4th Annual mRNA-based Therapeutics Summit taking place in Boston, MA. https://lnkd.in/e9xCKQxw #mRNASummit #WorldRNA #mRNATherapeutics #mRNAVaccines
-
-
Nature Magazine’s article “Serious errors plague DNA tool that’s a workhorse of biology” reveals significant flaws in plasmids, which are essential tools in biotherapeutic manufacturing and research. A study found that nearly half of the analyzed plasmids contained critical errors, potentially compromising experimental results. These errors often occur in sequences vital for gene expression and replication such as ITR regions and homopolymers. https://lnkd.in/dkpa9Avt ? Unlike plasmid DNA, our enzymatically produced LineaDNA and can rapidly produce DNA constructs containing challenging sequences such as ITRs and homopolymers that have high failure rates in plasmids. These sequences are critical for the manufacture of important therapies such as gene and mRNA therapies. Learn more about our LinearDNA platform:?https://linearxdna.com/
Serious errors plague DNA tool that’s a workhorse of biology
nature.com
-
“In partnership with Alphazyme LLC, we have now proved that our Linea RNAP, one of two core technologies comprising our Linea IVT platform, can be produced at scale and at a significantly lower unit cost to drive a material improvement in platform profitability.” #PCR #mRNA #GeneticMedicine #NucleicAcidBasedTherapies #DNAInnovation #CellFreeDNAProduction #SyntheticDNA #BiotechInnovation
Applied DNA and Alphazyme Conclude Linea? RNAP Manufacturing Scale-Up Project, Deliver Substantial Improvement in Linea? IVT Platform Economics
https://linearxdna.com
-
Applied DNA received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 18/302,247, entitled “Compositions and Methods for RNA Synthesis.” The resulting patent will cover the composition of the Company’s chemically modified RNA polymerase enzyme branded Linea? RNAP, with expected patent protection into 2041.?
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea? IVT Platform
adnas.com
-
An abstract relating to the development of a fully enzymatic, non-viral manufacturing workflow to enable the rapid and cost-effective production of clinical-grade (GMP) CAR T-cell therapies has been accepted for presentation at the prestigious European Hematology Association (EHA) 2024 Hybrid Congress to be held in Madrid, Spain. #EHA #HemaSphere
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA’s Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
https://linearxdna.com